Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Minerva Urol Nefrol ; 69(3): 285-292, 2017 Jun.
Article in English | MEDLINE | ID: mdl-27706124

ABSTRACT

BACKGROUND: To compare baseline characteristics and outcomes of patients undergoing GreenLight laser vaporization (GL) or transurethral resection of the prostate (TURP) in a real life setting. METHODS: In this prospective observational cohort, the Clinical Research Office of the Endourological Society (CROES) collected data of consecutive GL or TURP treated patients. Treatment involved one of three GL laser powers (80 W, 120 W or 180 W) based on availability in each participating centre, or TURP. Data on baseline characteristics as well as functional measures were collected at three time points: 6-12 weeks, 6, and 12months after surgery. Functional measures included urinary flow parameters, perceived prostate function (IPSS), perceived erectile function (IIEF-5) and complications. RESULTS: Seven hundred thirteen patients underwent GL, and 234 patients underwent TURP. Overall, patients treated with GL show higher BMI, IIEF and medication use, together with lower urinary function (voided volume, incontinence, urinary retention) at baseline. After the procedure, despite higher antibiotic and antimuscarinic use and shorter hospital stay, readmission rates, PVR, PSA were higher, but Qmax, and IIEF were lower in the GL group. The rate of post-operative complications was 10.3% and 5.2% for the TURP and GL group, respectively (P=0.006). CONCLUSIONS: We were unable to categorically state which procedure is superior. This observational study confirms that treatment decision for either TURP or GL is not based on patient characteristics.


Subject(s)
Laser Therapy/methods , Prostatic Hyperplasia/surgery , Transurethral Resection of Prostate/methods , Aged , Humans , Laser Therapy/instrumentation , Male , Prospective Studies , Transurethral Resection of Prostate/instrumentation , Treatment Outcome , Urinary Incontinence/etiology
2.
Can Urol Assoc J ; 9(9-10): E631-7, 2015.
Article in English | MEDLINE | ID: mdl-26425226

ABSTRACT

INTRODUCTION: Fibroepithelial polyps of the ureter are rare. Cases and small series are reported in the literature. The treatment of choice, outcome and appropriate follow-up regimen remain unclear. METHODS: We conducted a systematic literature review of papers reporting fibroepithelial polyps of the ureter in adult patients. Articles published before 1980 were excluded. RESULTS: The search yielded 144 papers, of which 68 met the inclusion criteria. A reference scan from the included 68 yielded an additional 7 new articles. In total, our study included 75 articles (68 + 7). A total of 134 patients were described. Most patients had a single lesion (range: 1-10). The median length of the polyp was 4.0 cm (range: 0.4-17.0). The percentage of polyps resected endoscopically increased from 0% before 1985 to 67% after 2005. Two perioperative complications were reported in 72 procedures (2.8%): a deep venous thrombosis and a case of mesenteric lymphadenopathy. Both of these occurred after open surgery. Follow-up data were available for 57 patients. The median follow-up was 12 months (range: 1-180). Four patients (7.0%) developed recurrent complaints: 2 had urinary stones, 1 had a ureteral stricture and 1 had recurrence of the polyp. Three of these events followed endoscopic resection, and occurred within a year after the procedure. CONCLUSION: Endoscopic resection of fibroepithelial polyps seems to be safe and effective. It is minimally invasive and should be considered the gold standard where endoscopic expertise is available. We advise follow-up imaging by computed tomographic intravenous urography after 3 months and ultrasound after 1 year to detect late complications.

3.
BJU Int ; 111(1): 148-56, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22578216

ABSTRACT

OBJECTIVES: To present the overall results of paediatric percutaneous nephrolithotomy (PCNL) compared with adults. To present the indications, complications and outcomes of patients treated in the participating centres in the PCNL Global Study, as categorised in different age groups. PATIENTS AND METHODS: The Clinical Research Office of the Endourological Society (CROES) Study was conducted from November 2007 to December 2009, and included 96 centres and >5800 patients. All children aged ≤14 years in the PCNL Global Study database were the focus of the study. RESULTS: In all, 107 children aged ≤14 years were included in the analysis. The PCNL procedure was conducted in 13 patients (12.1%) in the supine position; tubeless PCNL was performed in 15 patients (14%); and balloon dilatation was preferred in 22 patients (20.5%). The overall mean operative duration was 97.02 min; blood transfusion rate, fever and stone-free rates were 9%, 14% and 70.1%, respectively. A comparison of the paediatric PCNL cases according to age groups showed no statistically significant differences between the subgroups for patient characteristics, co-morbidities, renal anomalies, or previous surgical history. In the evaluation of the operative details, the mean sheath size and nephrostomy tube size were larger in school-age children than the preschool children (P = 0.01 and 0.002, respectively). There was a difference in the preferred methods for confirming stone-free status, with ultrasonography preferred more in preschool children (P < 0.001). The PCNL procedure position, puncture site, dilatation method, postoperative tube application, and surgical outcomes were comparable in school- and preschool-age children. While operative details showed some differences between children and adults, the surgical outcomes were comparable. CONCLUSIONS: A considerable number (45.7%) of the paediatric patients had a previous history of stone intervention. Based on the findings of the present study, we can suggest that PCNL can be applied safely and effectively in children in different age groups. Outcomes appear comparable with those in adults for the success and complication rates, in the presence of substantial indications, appropriate equipment and adequate experience.


Subject(s)
Kidney Calculi/therapy , Nephrostomy, Percutaneous/statistics & numerical data , Adolescent , Adult , Age Distribution , Analysis of Variance , Child , Child, Preschool , Female , Humans , Infant , Kidney/abnormalities , Lithotripsy/statistics & numerical data , Male , Nephrostomy, Percutaneous/adverse effects , Operative Time , Patient Positioning , Recurrence , Retreatment , Supine Position , Treatment Outcome , Young Adult
4.
Eur Urol ; 53(5): 984-91, 2008 May.
Article in English | MEDLINE | ID: mdl-18248876

ABSTRACT

OBJECTIVES: To study the additive effect of either an early instillation or maintenance instillations of adjuvant intravesical epirubicin, as compared to the epirubicin "standard" treatment schedule only, in patients with non-muscle-invasive bladder cancer. METHODS: Patients with intermediate- and high-risk urothelial cell carcinoma of the bladder, except carcinoma in situ, were randomised for adjuvant intravesical instillations with 50mg epirubicin/50 ml NaCl for 1h. Group 1 received 4 weekly and 5 monthly instillations (standard schedule), group 2 received the same schedule as group 1, but with an additional instillation <48 h after transurethral resection of bladder tumour (TURBT), and group 3 received the same scheme as group 1, but with additional instillations at 9 and 12 mo (maintenance schedule). Standard follow-up was 5 yr and consisted of cystoscopy, cytology, and registration of adverse events. RESULTS: A total of 731 patients were eligible for quasi intention-to-treat analysis. Side-effects were minimal for all treatment groups. After 5-yr follow-up, respectively, 44.4%, 42.7%, and 45.0% (log-rank test, p=0.712) of the patients in groups 1, 2, and 3 were recurrence free, and 90.0%, 87.7%, and 88.2% (log-rank test, p=0.593) of the patients, respectively, were progression free. CONCLUSIONS: In the quasi intention-to-treat analysis there is no difference in the 5-yr recurrence-free period between the treatment groups, despite one instillation within 48 h of TURBT or two maintenance instillations up to 1 yr, in addition to the "standard" schedule.


Subject(s)
Antibiotics, Antineoplastic/administration & dosage , Carcinoma, Transitional Cell/drug therapy , Epirubicin/administration & dosage , Neoplasm Invasiveness/pathology , Urinary Bladder Neoplasms/drug therapy , Administration, Intravesical , Adult , Aged , Aged, 80 and over , Carcinoma, Transitional Cell/pathology , Cystoscopy , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Staging , Prospective Studies , Treatment Outcome , Urinary Bladder Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...